review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Christine Katlama | Q47006550 |
Robert L. Murphy | Q39793026 | ||
P2860 | cites work | Trial and failure | Q59034419 |
AIDS research. Trials of NIH's AIDS vaccine get a yellow light | Q64376855 | ||
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals | Q79390358 | ||
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients | Q80176025 | ||
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme | Q45402590 | ||
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial | Q45405108 | ||
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection | Q46466415 | ||
Raltegravir | Q46519904 | ||
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase | Q46843159 | ||
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation | Q46852183 | ||
Vaginal microbicides: moving ahead after an unexpected setback. | Q50859418 | ||
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. | Q51740971 | ||
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? | Q24652185 | ||
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) | Q24656978 | ||
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study | Q28242324 | ||
A historical sketch of the discovery and development of HIV-1 integrase inhibitors | Q28274166 | ||
Raltegravir with optimized background therapy for resistant HIV-1 infection | Q28288290 | ||
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells | Q28369295 | ||
CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate | Q30479242 | ||
Integrase inhibitors to treat HIV/AIDS. | Q34397376 | ||
Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection | Q37039007 | ||
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection | Q37043546 | ||
Inhibitors of human immunodeficiency virus type I integration | Q37446895 | ||
Repair of gaps in retroviral DNA integration intermediates | Q39597824 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 2 | |
P304 | page(s) | 331-340 | |
P577 | publication date | 2009-04-01 | |
P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
P1476 | title | Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection | |
P478 | volume | 5 |
Q37775505 | Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors. |
Q37989555 | Dolutegravir for the treatment of HIV. |
Q37982825 | Elvitegravir: a once-daily inhibitor of HIV-1 integrase |
Q33991491 | Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors. |
Q42283539 | Synthesis and biological evaluation of novel antiviral agents as protein-protein interaction inhibitors |
Q38009758 | Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? |
Q40706247 | Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study. |
Search more.